🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping

Recruitingn/aAges 21 Years - anyAllSingapore Institute of Technology
NCT07804316 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This project aims to develop mapping of food choices available for chronic kidney disease (CKD) patients when dining out in Singapore. Following the mapping, a mobile application will be developed based on renal dining out food map mobile application (RENDOFOMAP) and trialed on patients with CKD. The specific aims of the project include: 1. Mapping out food choices suitable for patients with CKD when dining out in Singapore which will eventually be translated into a mobile application incorporating simple AI functionality. 2. To evaluate the impact of using RENDOFOMAP on self-empowerment, quality of life, nutritional status, and serum biochemistry in patients with CKD. 3. To evaluate the acceptability and user experience of RENDOFOMAP Participants with CKD will use the newly developed mobile application to find out if there is improvement in self-empowerment, quality of life, nutrition

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Are fluent in English. This is necessary to ensure clear communication and understanding of study procedures and materials. * Adequate proficiency in using smartphone i.e. downloading app, taking photo, completing e-forms within the mobile applications. This is essential for participants to effectively use the mobile application being tested. * Diagnosed with CKD Stage 3B-5. This targets the specific patient population that the study aims to benefit. Exclusion Criteria: * Only fluent in languages other than English. This could hinder effective communication and understanding of the study. * Diagnosis of cognitive deficit or neurological disorder. These conditions could impair the ability to follow study procedures or provide reliable data. * Uncontrolled diabetes (HbA1c\>8.5%). This condition could introduce additional health risks and confound study results. * Recent hypoglycemic episodes. This could pose a safety risk during the study. * Newly initiated on dialysis or planning for dialysis within the next 6 months. These patients may have rapidly changing health conditions that could affect study outcomes. * Decompensated liver cirrhosis. This condition could complicate the interpretation of study results. * Pregnant and lactating. These conditions could introduce additional variables that affect study outcomes. * Inability to provide consent. This ensures that all participants can legally and ethically participate in the study
💊

What it tests

  • Mobile application empowerment approach
📍

Where

1 site
Singapore Institute of Technology
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy